Table 1 Baseline demographics and disease characteristics
From: fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study
fSCIG 10% new starters (n = 23) | fSCIG 10% pretreated (n = 19) | Overall (N = 42) | |
|---|---|---|---|
Age, years† | |||
Mean (SD) | 10.3 (3.8) | 11.7 (4.3) | 11.0 (4.1) |
Median (range) | 11.0 (3–17) | 12.0 (3–17) | 11.5 (3–17) |
Age group, years, n (%) | |||
2 to < 6 years | 3 (13.0) | 3 (15.8) | 6 (14.3) |
6 to < 12 years | 11 (47.8) | 4 (21.1) | 15 (35.7) |
12 to < 18 years | 9 (39.1) | 12 (63.2) | 21 (50.0) |
Male sex, n (%) | 18 (78.3) | 16 (84.2) | 34 (81.0) |
Ethnicity, n (%) | |||
Not Hispanic or Latino | 23 (100) | 19 (100) | 42 (100) |
Race, n (%) | |||
White | 22 (95.7)‡ | 19 (100) | 41 (97.6)‡ |
BMI, kg/m2 | |||
Mean (SD) | 19.0 (4.3) | 20.4 (5.1) | 19.7 (4.6) |
Median (range) | 18.3 (12.3–30.3) | 18.8 (13.5–32.7) | 18.6 (12.3–32.7) |
PIDs diagnosis, n (%) | |||
Agammaglobulinemia – AR | 1 (4.3) | 1 (5.3) | 2 (4.8) |
Congenital agamma – XLA | 8 (34.8) | 8 (42.1) | 16 (38.1) |
Common variable immunodeficiency | 11 (47.8) | 7 (36.8) | 18 (42.9) |
Severe combined immune deficiency | 0 | 1 (5.3) | 1 (2.4) |
Activated phosphokinase 3 delta receptor syndrome§ | 0 | 1 (5.3) | 1 (2.4) |
Hypogammaglobulinemia§ | 1 (4.3) | 0 | 1 (2.4) |
NEMO immune deficiency§ | 2 (8.7) | 0 | 2 (4.8) |
PI3K-delta syndrome§ | 0 | 1 (5.3) | 1 (2.4) |